AR116592A1 - Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib - Google Patents
Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinibInfo
- Publication number
- AR116592A1 AR116592A1 ARP190102822A ARP190102822A AR116592A1 AR 116592 A1 AR116592 A1 AR 116592A1 AR P190102822 A ARP190102822 A AR P190102822A AR P190102822 A ARP190102822 A AR P190102822A AR 116592 A1 AR116592 A1 AR 116592A1
- Authority
- AR
- Argentina
- Prior art keywords
- cholangitis
- baricitinib
- primary
- treatment
- primary biliary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Métodos para tratar la colangitis biliar primaria y/o la colangitis esclerosante primaria con baricitinib, lo cual incluye formulaciones y regímenes de dosis. La cantidad de baricitinib puede administrarse como un comprimido o píldora de 4 mg que incluye uno o más excipientes. La cantidad de baricitinib puede administrarse diariamente o a razón de alguna otra frecuencia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746589P | 2018-10-17 | 2018-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR116592A1 true AR116592A1 (es) | 2021-05-26 |
Family
ID=68345083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102822A AR116592A1 (es) | 2018-10-17 | 2019-10-03 | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11197860B2 (es) |
| EP (1) | EP3866806A1 (es) |
| JP (1) | JP7140914B2 (es) |
| CN (1) | CN112823007B (es) |
| AR (1) | AR116592A1 (es) |
| AU (1) | AU2019361766B2 (es) |
| CA (1) | CA3116338C (es) |
| TW (1) | TW202033198A (es) |
| WO (1) | WO2020081346A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827597B (zh) * | 2021-06-07 | 2023-06-20 | 天津济坤医药科技有限公司 | 化合物在制备治疗特发性肺纤维化的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA017218B1 (ru) | 2008-03-11 | 2012-10-30 | Инсайт Корпорейшн | Производные азетидина и циклобутана как ингибиторы jak-киназ |
| NO2721710T3 (es) * | 2014-08-21 | 2018-03-31 | ||
| AR104918A1 (es) | 2015-06-19 | 2017-08-23 | Lilly Co Eli | Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo |
| EA035036B1 (ru) | 2016-02-24 | 2020-04-20 | Пфайзер Инк. | Производные пиразоло[1,5-а]пиразин-4-ила в качестве ингибиторов янус-киназы (jak) |
| US20180117148A1 (en) * | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
| CN106946917B (zh) * | 2017-03-20 | 2019-06-11 | 杭州科巢生物科技有限公司 | 一种jak抑制剂巴瑞替尼及其中间体的新合成方法 |
-
2019
- 2019-10-03 AR ARP190102822A patent/AR116592A1/es unknown
- 2019-10-03 TW TW108135837A patent/TW202033198A/zh unknown
- 2019-10-10 JP JP2021520400A patent/JP7140914B2/ja active Active
- 2019-10-10 CN CN201980068527.9A patent/CN112823007B/zh active Active
- 2019-10-10 EP EP19794841.7A patent/EP3866806A1/en active Pending
- 2019-10-10 CA CA3116338A patent/CA3116338C/en active Active
- 2019-10-10 US US16/598,241 patent/US11197860B2/en active Active
- 2019-10-10 AU AU2019361766A patent/AU2019361766B2/en active Active
- 2019-10-10 WO PCT/US2019/055566 patent/WO2020081346A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020081346A1 (en) | 2020-04-23 |
| JP7140914B2 (ja) | 2022-09-21 |
| CN112823007B (zh) | 2024-01-05 |
| AU2019361766B2 (en) | 2023-02-02 |
| CA3116338A1 (en) | 2020-04-23 |
| US20200121685A1 (en) | 2020-04-23 |
| CN112823007A (zh) | 2021-05-18 |
| US11197860B2 (en) | 2021-12-14 |
| CA3116338C (en) | 2023-12-19 |
| EP3866806A1 (en) | 2021-08-25 |
| AU2019361766A1 (en) | 2021-04-01 |
| TW202033198A (zh) | 2020-09-16 |
| JP2022504903A (ja) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
| MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
| CO2018006358A2 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| MX2021005992A (es) | Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión. | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| MX2022007391A (es) | Compuestos activos frente a receptores nucleares. | |
| MX2022007265A (es) | Compuestos activos frente a receptores nucleares. | |
| CY1119522T1 (el) | (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| AR116592A1 (es) | Tratamiento de la colangitis biliar primaria y la colangitis esclerosante primaria con baricitinib | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| AR102308A1 (es) | Composición farmacéutica para usar en el tratamiento o prevención de deficiencias de vitaminas y minerales en pacientes sometidos a cirugía de bypass gástrico | |
| MX2023015097A (es) | Tratamiento de sintomas asociados a neoplasias mieloproliferativas. | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| MX2019013014A (es) | Tratamiento de carcinoma hepatocelular. | |
| MX2018012193A (es) | Tratamiento de carcinoma de celulas renales con lenvatinib y everolimus. | |
| CO2021006279A2 (es) | Métodos y tratamientos para la disfunción eréctil | |
| MX2024001154A (es) | Tratamiento del eczema de manos con baricitinib. | |
| CO2020010047A2 (es) | Métodos de terapia de testosterona |